DarioHealth Corp. is a digital therapeutics enterprise operating across the United States, Canada, the European Union, Australia, and New Zealand. The company delivers a suite of digital health solutions, including its 'Dario' metabolic programs designed to address conditions like diabetes, hypertension, and weight man…
An institutional-grade, numbers-driven thesis on DRIO — generated on demand from live fundamentals, scores and forecast.
Member feature · 7-day free trial · no charge today · cancel anytime
As of July 4, 2026, TradersQuant's model rates DarioHealth Corp. (DRIO) 65/100 with a 12-month base-case forecast of $12.50 — +71.7% versus the current price of $7.28. DarioHealth Corp. trades at $7.28 in the Healthcare sector, with a market capitalisation of $53.2M. The score blends valuation, growth, earnings quality and momentum into a single grade.
The 12-month analyst consensus price target for DRIO is $12.50, implying +71.7% versus the current price. The model's 12-month scenario range runs from $7.85 (bear) to $10.70 (bull), with a base case of $8.86.
On the fundamentals, DarioHealth shows a P/E of 3.2, trailing revenue of $22.4M, revenue growth of -17.3% YoY. This page also tracks DRIO's short interest, institutional (smart-money) positioning and the options market — the same cross-signal view institutions watch.
DRIO currently carries a TradersQuant composite score of 65/100, which we read as a neutral-to-watch signal. The Wall-Street analyst consensus is "Buy". Our 12-month price target of $12.50 implies +71.7% from $7.28. This is research, not financial advice — always combine it with your own judgement.
The analyst consensus price target for DRIO is $12.50, about +71.7% versus the latest price of $7.28. Consensus is based on 9 analysts.
TradersQuant's 12-month model forecast for DRIO is a base case of $8.86, ranging from $7.85 (bear) to $10.70 (bull), an expected return of +21.7%. Forecasts are model estimates, not guarantees.
The TradersQuant price prediction for DRIO over the next 12 months is $8.86 in the base case (bear $7.85, bull $10.70), versus today's price of $7.28. Unlike black-box prediction sites, every TradersQuant call is logged at the price and date it was made and graded publicly against the S&P 500.
We deliberately don't publish 2030 price predictions for DRIO — no model can honestly forecast a single stock five-plus years out, and sites that do are guessing. TradersQuant focuses on a rigorous 12-month bull/base/bear range, refreshed continuously and graded on our public track record.
TradersQuant estimates DRIO's fair value at $12.50, implying +71.7% of expected upside versus the current price.
DarioHealth does not currently pay a dividend.
Data and model outputs are for research only and are not financial advice. Figures update continuously.
